<DOC>
	<DOC>NCT01039038</DOC>
	<brief_summary>The objective of the trial is to evaluating the feasibility of dose increase by a boost of curietherapy in PDR (at least 40 Gy on D95) associated to extern radiotherapy (34 Gy) in intermediate risk in prostate cancer.</brief_summary>
	<brief_title>Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age ≥ 50 years and ≤ 75 years Life expectancy &gt;10 years Localized prostatic adenocarcinoma and histologically proven Intermediate risk cancer(T2b or PSA between 10 and 20 or Gleason = 7(3+4) according to Amico criteria Metastasis or pelvic pathologic ganglion (≥ 10 mm) absence OMS &lt; 2 No previous treatment by radiotherapy and/or curietherapy Hormonotherapy authorized before and during the study Rectal or ureterovesical pathology Signed informed consent Social security system affiliation Individual deprived of liberty or placed under the authority of a tutor. No anesthesia contraindication Adenocarcinoma not histologically proven Metastases presence Pathological nodes presence(≥ 10 mm) Prior prostate endoscopic resection history of other malignancy except for appropriately treated superficial basal cell skin cancer Medical contraindications to anesthesia Patients with uncontrolled psychiatric disease or medical disease incompatible with the protocol Impossibility to respect the medical followup of the protocol for geographical, social or psychic reasons</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>prostate</keyword>
	<keyword>curietherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>intermediate risk</keyword>
</DOC>